HUP0203669A2 - Renin inhibitorok, eljárás az előállításukra, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk - Google Patents
Renin inhibitorok, eljárás az előállításukra, ezeket tartalmazó gyógyszerkészítmények és alkalmazásukInfo
- Publication number
- HUP0203669A2 HUP0203669A2 HU0203669A HUP0203669A HUP0203669A2 HU P0203669 A2 HUP0203669 A2 HU P0203669A2 HU 0203669 A HU0203669 A HU 0203669A HU P0203669 A HUP0203669 A HU P0203669A HU P0203669 A2 HUP0203669 A2 HU P0203669A2
- Authority
- HU
- Hungary
- Prior art keywords
- carbon
- alkoxy
- hydrogen atom
- alkyl
- group
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 239000002461 renin inhibitor Substances 0.000 title 1
- 229940086526 renin-inhibitors Drugs 0.000 title 1
- -1 hydroxymethyl- Chemical group 0.000 abstract 4
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 2
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 abstract 1
- 208000010412 Glaucoma Diseases 0.000 abstract 1
- 206010019280 Heart failures Diseases 0.000 abstract 1
- 206010020772 Hypertension Diseases 0.000 abstract 1
- 208000001647 Renal Insufficiency Diseases 0.000 abstract 1
- 125000003545 alkoxy group Chemical group 0.000 abstract 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 abstract 1
- 229910052799 carbon Inorganic materials 0.000 abstract 1
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 1
- 230000006806 disease prevention Effects 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 150000002367 halogens Chemical class 0.000 abstract 1
- 201000006370 kidney failure Diseases 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 208000010125 myocardial infarction Diseases 0.000 abstract 1
- 125000001624 naphthyl group Chemical group 0.000 abstract 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 1
- 230000008816 organ damage Effects 0.000 abstract 1
- 239000000825 pharmaceutical preparation Substances 0.000 abstract 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 1
- 208000037803 restenosis Diseases 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 125000001425 triazolyl group Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/40—Oxygen atoms
- C07D211/42—Oxygen atoms attached in position 3 or 5
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Ophthalmology & Optometry (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Pyridine Compounds (AREA)
Abstract
Az (I) általános képletű vegyületek[mely képletben R1 jelentése adottesetben egy-három 1-5 szénatomos alkoxicsoporttal helyettesítettnaftilcsoport; R2 jelentése adott esetben egy-három azonos vagykülönböző halogén-, ciano-, 1-3 szénatomos alkoxi- és/vagynitrohelyettesítőt hordozó fenil- vagy benzilcsoport; R3 jelentésehidroxi-metil-, imidazolil-metil-, triazolil-metil-, H-[CH(OR4)]2-CH2-, vagy H-[CH(OR4)]2-CH2-O-CH2- vagy R3a-(CH2)k-[CH(OR4)]1-CH2-O-csoport; R3a jelentése hidrogénatom, hidroxil-, imidazolil-,triazolil-, 1-3 szénatomos alkoxi-, 1-3 szénatomos alkoxi-(2-3szénatomos alkoxi)-, hidroxi-(2-3 szénatomos alkoxi)-, 1-3 szénatomosalkil-amino- vagy di-(1-3 szénatomos alkil)-amino-csoport; R4jelentése hidrogénatom vagy 1-3 szénatomos alkilcsoport; k értéke 1vagy 2, ha R3 jelentése hidrogénatom, k értéke 0; 1 értéke 1 vagy 2]és gyógyászatilag alkalmas sóik restenózissal, glaukomával,szívinfarktussal, magasvérnyomással és szervi károsodásokkal, pl.szívelégtelenséggel és veseelégtelenséggel társult betegségekkezelésére és megelőzésére alkalmazhatók. A találmány kiterjed az (I)általános képletű vegyületek előállítására és ezeket taratlmazógyógyszerkészítményekre is. Ó
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP99108199 | 1999-04-27 | ||
PCT/EP2000/003555 WO2000064873A1 (en) | 1999-04-27 | 2000-04-19 | Renin inhibitors |
Publications (3)
Publication Number | Publication Date |
---|---|
HUP0203669A2 true HUP0203669A2 (hu) | 2003-02-28 |
HUP0203669A3 HUP0203669A3 (en) | 2003-12-29 |
HU227764B1 HU227764B1 (en) | 2012-02-28 |
Family
ID=8238050
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HU0203669A HU227764B1 (en) | 1999-04-27 | 2000-04-19 | Renin inhibitors, process for their preparation, pharmaceutical compositions containing them and their use |
Country Status (35)
Country | Link |
---|---|
US (2) | US6376672B1 (hu) |
EP (1) | EP1175400B1 (hu) |
JP (1) | JP3808706B2 (hu) |
KR (1) | KR100443684B1 (hu) |
CN (1) | CN1147471C (hu) |
AR (2) | AR018719A1 (hu) |
AT (1) | ATE512949T1 (hu) |
AU (1) | AU763718B2 (hu) |
BR (1) | BR0010080B1 (hu) |
CA (1) | CA2370888C (hu) |
CO (1) | CO5170513A1 (hu) |
CZ (1) | CZ302012B6 (hu) |
DK (1) | DK1175400T3 (hu) |
EG (1) | EG23979A (hu) |
ES (1) | ES2366668T3 (hu) |
GC (1) | GC0000251A (hu) |
HK (1) | HK1045999B (hu) |
HR (1) | HRP20010762A2 (hu) |
HU (1) | HU227764B1 (hu) |
IL (2) | IL146002A0 (hu) |
JO (1) | JO2256B1 (hu) |
MA (1) | MA26787A1 (hu) |
MX (1) | MXPA01010934A (hu) |
MY (1) | MY127894A (hu) |
NO (1) | NO320803B1 (hu) |
NZ (1) | NZ514981A (hu) |
PE (1) | PE20010069A1 (hu) |
PL (1) | PL199895B1 (hu) |
PT (1) | PT1175400E (hu) |
RS (1) | RS51156B (hu) |
RU (1) | RU2213731C2 (hu) |
TR (1) | TR200103095T2 (hu) |
TW (1) | TWI224593B (hu) |
WO (1) | WO2000064873A1 (hu) |
ZA (1) | ZA200108735B (hu) |
Families Citing this family (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6376672B1 (en) * | 1999-04-27 | 2002-04-23 | Hoffmann-La Roche Inc. | Naphthalenylmethoxypiperidines as renin inhibitors |
US6835686B2 (en) * | 2001-07-05 | 2004-12-28 | Millennium Specialty Chemicals | Catalyst system and process for rearrangement of epoxides to allylic alcohols |
BR0312000A (pt) * | 2002-06-27 | 2005-03-22 | Actelion Pharmaceuticals Ltd | Compostos, composições farmacêuticas, método para o tratamento ou profilaxia de doenças, e, uso dos compostos |
US20040214832A1 (en) * | 2003-04-10 | 2004-10-28 | Cuiman Cai | Piperazine derivative renin inhibitors |
DE602004010385D1 (de) * | 2003-04-29 | 2008-01-10 | Actelion Pharmaceuticals Ltd | 3,4-disubstituierte 1,2,3,4-tetrahydropyridinderivate |
TW200900399A (en) * | 2003-10-01 | 2009-01-01 | Speedel Experimenta Ag | Organic compounds |
AR045950A1 (es) * | 2003-10-09 | 2005-11-16 | Speedel Experimenta Ag | Compuestos derivados de piperazina, composiciones farmaceuticas que los contienen y su uso en la fabricacion de medicamentos. |
WO2005037317A2 (en) * | 2003-10-17 | 2005-04-28 | Cornell Research Foundation, Inc. | Mast cell-derived renin |
CA2546264A1 (en) * | 2003-11-26 | 2005-06-09 | Novartis Ag | 4-phenylpiperidine derivatives as renin inhibitors |
AR053406A1 (es) * | 2004-07-09 | 2007-05-09 | Speedel Experimenta Ag | Derivados de piperidina como inhibidores de renina. composiciones farmaceuticas |
EP1799199B1 (en) | 2004-10-08 | 2012-03-28 | Novartis AG | Use of renin inhibitors for the prevention or treatment of diastolic dysfunction or diastolic heart failure |
GB0428526D0 (en) | 2004-12-30 | 2005-02-09 | Novartis Ag | Organic compounds |
GB0500784D0 (en) * | 2005-01-14 | 2005-02-23 | Novartis Ag | Organic compounds |
EP1707202A1 (de) * | 2005-03-31 | 2006-10-04 | Speedel Experimenta AG | Organische Verbindungen |
AR055756A1 (es) * | 2005-03-31 | 2007-09-05 | Speedel Experimenta Ag | Piperidinas sustituidas; procesos de preparacion y su uso como medicamentos |
TW200722424A (en) * | 2005-03-31 | 2007-06-16 | Speedel Experimenta Ag | Substituted piperidines |
EP1897879A3 (en) * | 2005-03-31 | 2008-06-11 | Speedel Experimenta AG | 2,4,5-substituted piperidines as renin inhibitors |
BRPI0609534A2 (pt) * | 2005-03-31 | 2010-04-13 | Speedel Experimenta Ag | piperidinas 3,4,5-substituìdas |
ES2352564T3 (es) * | 2005-03-31 | 2011-02-21 | Novartis Ag | Piperidinas sustituidas. |
JP4297972B2 (ja) | 2005-05-27 | 2009-07-15 | アクテリオン ファーマシューティカルズ リミテッド | 新規なピペリジンカルボン酸アミド誘導体 |
GB0514203D0 (en) * | 2005-07-11 | 2005-08-17 | Novartis Ag | Organic compounds |
BRPI0617621A2 (pt) * | 2005-10-21 | 2011-08-02 | Novartis Ag | combinação de compostos orgánicos |
CN101356156B (zh) * | 2005-11-14 | 2012-12-05 | 生命医药公司 | 天冬氨酸蛋白酶抑制剂 |
PT2420491E (pt) * | 2005-12-30 | 2013-10-14 | Novartis Ag | Compostos de piperidina 3,5-substituída como inibidores de renina |
TW200804359A (en) | 2006-01-19 | 2008-01-16 | Speedel Experimenta Ag | Substituted 4-phenylpiperidines |
EP1816122A3 (en) * | 2006-01-19 | 2007-09-19 | Speedel Experimenta AG | 3,4,5-substituted piperidines as therapeutic compounds |
TW200821303A (en) * | 2006-08-08 | 2008-05-16 | Speedel Experimenta Ag | Organic compounds |
WO2008021552A2 (en) * | 2006-08-18 | 2008-02-21 | Duke University | Biased ligands and methods of identifying same |
EP1908761A1 (en) * | 2006-10-04 | 2008-04-09 | Speedel Experimenta AG | Organic compounds |
EP1911758A1 (en) * | 2006-10-04 | 2008-04-16 | Speedel Experimenta AG | Phenyl piperidine derivatives for use as renin inhibitors |
ES2541107T3 (es) | 2007-06-25 | 2015-07-16 | Novartis Ag | Derivados de N5-(2-etoxietil)-N3-(2-piridinil)-3,5-piperidindicarboxamida para su uso como inhibidores de renina |
JP2011503022A (ja) * | 2007-11-02 | 2011-01-27 | ノバルティス アーゲー | レニン阻害剤としての4,4−二置換ピペリジン |
US10517839B2 (en) | 2008-06-09 | 2019-12-31 | Cornell University | Mast cell inhibition in diseases of the retina and vitreous |
WO2011045244A1 (en) | 2009-10-14 | 2011-04-21 | Rainer Oberbauer | Acute kidney injury risk testing |
WO2013045505A1 (en) | 2011-09-28 | 2013-04-04 | Novartis Ag | Biomarkers for raas combination therapy |
EP2810644A1 (en) | 2013-06-06 | 2014-12-10 | Ferrer Internacional, S.A. | Oral formulation for the treatment of cardiovascular diseases |
WO2018002673A1 (en) | 2016-07-01 | 2018-01-04 | N4 Pharma Uk Limited | Novel formulations of angiotensin ii receptor antagonists |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK231088D0 (da) | 1988-04-28 | 1988-04-28 | Ferrosan As | Piperidinforbindelser, deres fremstilling og anvendelse |
DE3640475A1 (de) | 1986-11-27 | 1988-06-09 | Hoechst Sa Lab | Arzneimittel auf basis von derivaten des 3,4-diphenylpiperidins, die verwendung der derivate als arzneimittel sowie neue 3,4-diphenylpiperidinderivate und verfahren zu ihrer herstellung |
WO1993000042A1 (en) | 1991-06-24 | 1993-01-07 | B.V. Optische Industrie 'de Oude Delft' | Device for measuring the respiration of a person |
WO1997003911A1 (de) | 1995-07-24 | 1997-02-06 | Railfix N.V. | Elektro-permanentmagnetsystem zum manövrieren von einer magnetischen insbesondere ferromagnetischen last |
CN1256326C (zh) | 1995-09-07 | 2006-05-17 | 弗·哈夫曼-拉罗切有限公司 | 治疗心脏和肾功能不全的新型4-(氧烷氧基苯基)-3-氧哌啶化合物 |
AU9740998A (en) * | 1997-09-08 | 1999-03-29 | F. Hoffmann-La Roche Ag | Piperidine derivatives against malaria |
US6376672B1 (en) * | 1999-04-27 | 2002-04-23 | Hoffmann-La Roche Inc. | Naphthalenylmethoxypiperidines as renin inhibitors |
-
2000
- 2000-04-04 US US09/542,303 patent/US6376672B1/en not_active Expired - Fee Related
- 2000-04-19 HU HU0203669A patent/HU227764B1/hu not_active IP Right Cessation
- 2000-04-19 TR TR2001/03095T patent/TR200103095T2/xx unknown
- 2000-04-19 PL PL353442A patent/PL199895B1/pl not_active IP Right Cessation
- 2000-04-19 BR BRPI0010080-3A patent/BR0010080B1/pt not_active IP Right Cessation
- 2000-04-19 CA CA002370888A patent/CA2370888C/en not_active Expired - Fee Related
- 2000-04-19 PT PT00922651T patent/PT1175400E/pt unknown
- 2000-04-19 IL IL14600200A patent/IL146002A0/xx active IP Right Grant
- 2000-04-19 RS YUP-771/01A patent/RS51156B/sr unknown
- 2000-04-19 ES ES00922651T patent/ES2366668T3/es not_active Expired - Lifetime
- 2000-04-19 EP EP00922651A patent/EP1175400B1/en not_active Expired - Lifetime
- 2000-04-19 TW TW089107377A patent/TWI224593B/zh not_active IP Right Cessation
- 2000-04-19 AT AT00922651T patent/ATE512949T1/de active
- 2000-04-19 RU RU2001130163/04A patent/RU2213731C2/ru not_active IP Right Cessation
- 2000-04-19 WO PCT/EP2000/003555 patent/WO2000064873A1/en active IP Right Grant
- 2000-04-19 NZ NZ514981A patent/NZ514981A/xx not_active IP Right Cessation
- 2000-04-19 CN CNB008068003A patent/CN1147471C/zh not_active Expired - Fee Related
- 2000-04-19 KR KR10-2001-7013696A patent/KR100443684B1/ko not_active IP Right Cessation
- 2000-04-19 AU AU42968/00A patent/AU763718B2/en not_active Ceased
- 2000-04-19 JP JP2000613826A patent/JP3808706B2/ja not_active Expired - Fee Related
- 2000-04-19 CZ CZ20013854A patent/CZ302012B6/cs not_active IP Right Cessation
- 2000-04-19 MX MXPA01010934A patent/MXPA01010934A/es active IP Right Grant
- 2000-04-19 DK DK00922651.5T patent/DK1175400T3/da active
- 2000-04-23 JO JO200063A patent/JO2256B1/en active
- 2000-04-24 EG EG20000523A patent/EG23979A/xx active
- 2000-04-25 PE PE2000000386A patent/PE20010069A1/es not_active Application Discontinuation
- 2000-04-25 GC GCP2000632 patent/GC0000251A/en active
- 2000-04-25 MY MYPI20001771A patent/MY127894A/en unknown
- 2000-04-26 AR ARP000101954A patent/AR018719A1/es active IP Right Grant
- 2000-04-26 CO CO00029975A patent/CO5170513A1/es not_active Application Discontinuation
-
2001
- 2001-10-17 IL IL146002A patent/IL146002A/en not_active IP Right Cessation
- 2001-10-19 HR HR20010762A patent/HRP20010762A2/xx not_active Application Discontinuation
- 2001-10-23 ZA ZA200108735A patent/ZA200108735B/xx unknown
- 2001-10-25 NO NO20015206A patent/NO320803B1/no not_active IP Right Cessation
- 2001-10-26 MA MA26386A patent/MA26787A1/fr unknown
- 2001-12-18 US US10/023,679 patent/US6673931B2/en not_active Expired - Fee Related
-
2002
- 2002-10-22 HK HK02107639.0A patent/HK1045999B/zh not_active IP Right Cessation
-
2009
- 2009-02-25 AR ARP090100634A patent/AR070473A2/es active IP Right Grant
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HUP0203669A2 (hu) | Renin inhibitorok, eljárás az előállításukra, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk | |
HUP9600448A2 (hu) | Naftilvegyületek, e vegyületeket tartalmazó gyógyszerkészítmények, eljárás előállításukra, intermedierjeik és alkalmazásuk | |
HUP0301120A2 (hu) | Szubsztituált fenilamino-kinazolin-származékok, alkalmazásuk rendellenes sejtnövekedés kezelésére és azokat tartalmazó gyógyszerkészítmények | |
HUP0002347A2 (hu) | Hidantoin-, oxazol- és pirrolszármazékok alkalmazása gyulladásos betegségek kezelésére alkalmazható gyógyszerkészítmények előállítására | |
HUP0004559A1 (hu) | Ciklinfüggő kinázok aminotiazol inhibitorai, az ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk | |
AU525094B2 (en) | 1-phenyl-2-aminoethanol derivatives | |
HUP0401339A2 (hu) | Új 4-anilino-3-kinolinkarboxamidok, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények | |
HUP0001555A2 (hu) | Tetrahidro-imidazo-naftiridin származékok, ezeket tartalmazó gyógyszerkészítmények és eljárás előállításukra | |
HUP0302487A2 (hu) | Új mandulasavszármazékok és felhasználásuk trombin inhibitorokként, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények | |
HUP0104693A2 (hu) | Eljárás az ízületi gyulladás MEK inhibitorokkal való kezelésére | |
HUP9802433A2 (hu) | 8-Azabiciklo[3.2.1]okt-2-én-származékok, eljárás előállításukra és alkalmazásuk | |
HUP0100225A2 (hu) | Karboxamido-tiazol-származékok, előállításuk és az ezeket tartalmazó gyógyszerkészítmények | |
HUP0002528A2 (hu) | Xa faktort gátló hatású heterociklusos vegyületek | |
HUP9701193A2 (hu) | N-(4-Aril-tiazol-2-il)-szulfonamid-származékok alkalmazása neurológiai rendellenességek kezelésére szolgáló gyógyszerkészítmények előállítására, új származékok, eljárás előállításukra és az ezeket tartalmazó gyógyszerkészítmények | |
HUP0402225A2 (hu) | Makrolid-vegyületek, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények | |
HUP9801219A2 (hu) | Triciklusos N-acilezett benzazepin és benzoxazepinszármazékok, az ezeket tartalmazó gyógyszerkészítmények, eljárás előállításukra | |
HUP9900851A2 (hu) | Benzotiofénszármazékok felhasználása véredény simaizom sejtek migrálásának inhibiálására alkalmas gyógyszerkészítmények előállítására | |
HUP0303539A2 (hu) | Fenilszármazékok, eljárás az előállításukra, alkalmazásuk és ezeket tartalmazó gyógyszerkészítmények | |
NO20010487L (no) | Disubstituert maleimidforbindelse og farmasøytisk anvendelse herav | |
UA26368A (uk) | Спосіб одержаhhя похідhих оксадіазолалкілпуриhу або їх фармацевтичhо прийhятhих кислотhо-адитивhих солей (варіаhти) | |
MD382C2 (ro) | Procedeu de obţinere a piperazinilalchil-3(2H)-piridazinonelor sau a sărurilor lor farmaceutice admisibile | |
NO961000L (no) | Piperidinderivater, fremgangsmåte for fremstilling derav og medikament og preparat inneholdende slike | |
HUP0003577A2 (hu) | Tetrahidro-gamma-karbolinok, eljárás előállításukra, alkalmazásuk és az ezeket tartalmazó gyógyszerkészítmények | |
NO900697L (no) | Fremgangsmaate for fremstilling av terapeutisk aktive acetamid-derivater. | |
CA2053477A1 (en) | Heterocyclic amine derivatives, their production and use |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MM4A | Lapse of definitive patent protection due to non-payment of fees |